App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trial
CONCLUSION: Patients with breast cancer suffer from psychological problems including anxiety and depression during and after therapy. Personalized, supportive care with the app PINK! Coach turned out as a promising opportunity to significantly improve psychological distress in a convenient, accessible, and low-threshold manner for breast cancer patients independent of their stage of disease (EBC/MBC), therapy phase (aftercare or therapy) or therapy itself (chemotherapy/other therapy options). The app is routinely available in Germany as a DiGA. Clinical Trial Registration: DRKS Trial Registry (DRKS00028699).PMID:38699636 |...
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Josefine Wolff Svenja Seidel Pia Wuelfing Michael Patrick Lux Christine Zu Eulenburg Martin Smollich Freerk Baumann Stephan Seitz Sherko Kuemmel Marc Thill Joke Tio Michael Braun Hannah Hollaender Angenla Seitz Felicitas Horn Nadia Harbeck Rachel Wuerstle Source Type: research
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Camb Prism Precis Med. 2024 Mar 26;2:e4. doi: 10.1017/pcm.2024.1. eCollection 2024.ABSTRACTThe personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the 'molecular tumour board' into 'standard of care' ensures a unified clinical de...
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Nesrine Lajmi Sofia Alves-Vasconcelos Apostolos Tsiachristas Andrew Haworth Kerrie Woods Charles Crichton Theresa Noble Hizni Salih Kinga A V árnai Harriet Branford-White Liam Orrell Andrew Osman Kevin M Bradley Lara Bonney Daniel R McGowan Jim Davies Ma Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Contemporary Management of Pediatric Brainstem Tumors
Adv Tech Stand Neurosurg. 2024;49:231-254. doi: 10.1007/978-3-031-42398-7_11.ABSTRACTBrain tumors are the second most common malignancy in childhood. Around 15-20% of pediatric brain tumors occur in the brainstem. The most common type of brainstem tumor are diffuse tumors in the ventral pons, whereas focal tumors tend to arise from the midbrain, medulla, and dorsal pons. Glioma is the most common pathological entity. Contemporary management consists of surgery, radiotherapy, chemotherapy, and other adjuvant treatment. Surgical options range from biopsy to radical excision. Biopsy can be performed for diagnostic and prognos...
Source: Advances and Technical Standards in Neurosurgery - May 3, 2024 Category: Neurosurgery Authors: Sheng-Che Chou Yu-Ning Chen Hsin-Yi Huang Meng-Fai Kuo Tai-Tong Wong Sung-Hsin Kuo Shih-Hung Yang Source Type: research
Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement
Med J Aust. 2024 May 3. doi: 10.5694/mja2.52295. Online ahead of print.ABSTRACTINTRODUCTION: The main mission of the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG) is to develop and facilitate local access to the world's leading evidence-based clinical trials for all paediatric cancers, including brain tumours, as soon as practically possible. Diffuse intrinsic pontine gliomas (DIPGs) - a subset of a larger group of tumours now termed diffuse midline glioma, H3K27-altered (DMG) - are paediatric brain cancers with less than 10% survival at two years. In the absence of any proven curative ther...
Source: Medical Journal of Australia - May 3, 2024 Category: General Medicine Authors: Santosh Valvi Neevika Manoharan Marion K Mateos Timothy Eg Hassall David S Ziegler Geoffrey B McCowage Matthew D Dun David D Eisenstat Nicholas G Gottardo Jordan R Hansford Source Type: research
Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view
Int Immunopharmacol. 2024 May 2;134:112171. doi: 10.1016/j.intimp.2024.112171. Online ahead of print.ABSTRACTProstate cancer represents the second most prevalent form of cancer found in males, and stands as the fifth primary contributor to cancer-induced mortality on a global scale. Research has shown that transplanted mesenchymal stem cells (MSCs) can migrate by homing to tumor sites in the body. In prostate cancer, researchers have explored the fact that MSC-based therapies (including genetically modified delivery vehicles or vectors) and MSC-derived exosomes are emerging as attractive options to improve the efficacy and...
Source: International Immunopharmacology - May 3, 2024 Category: Allergy & Immunology Authors: Fahimeh Lavi Arab Akram Hoseinzadeh Fatemeh Hafizi Fatemeh Sadat Mohammadi Farid Zeynali Melika Hadad Tehran Amirreza Rostami Source Type: research
Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials
ConclusionWe found that FDA-approved indications for ramucirumab had better efficacy outcomes than non-approved indications. However, a concerning number of adverse events were observed across all trials assessed. Participants in ramucirumab randomized controlled trials saw meager gains in overall survival when evaluated against a comparison group. Clinicians should carefully weigh the risks associated with ramucirumab therapy given its toxicity burden and poor survival gains. (Source: Cancer Medicine)
Source: Cancer Medicine - May 3, 2024 Category: Cancer & Oncology Authors: Adam Khan,
Hassan Khan,
Griffin K. Hughes,
Chase Ladd,
Ryan McIntire,
Brooke Gardner,
Andriana M. Pe ña,
Abigail Schoutko,
Jordan Tuia,
Kirstien Minley,
Alyson Haslam,
Vinay Prasad,
Matt Vassar Tags: RESEARCH ARTICLE Source Type: research
Radiation therapy for ventricular arrhythmias
This article summarises the current evidence for this novel treatment modality and the steps that will be required to bring it to the forefront of VA treatment. (Source: Journal of Medical Imaging and Radiation Oncology)
Source: Journal of Medical Imaging and Radiation Oncology - May 3, 2024 Category: Radiology Authors: Xingzhou Liulu,
Poornima Balaji,
Jeffrey Barber,
Kasun De Silva,
Tiarne Murray,
Andrew Hickey,
Timothy Campbell,
Jill Harris,
Harriet Gee,
Verity Ahern,
Saurabh Kumar,
Eric Hau,
Pierre C Qian Tags: Radiation Oncology —Review Article Source Type: research
GSE234614 Osteosarcoma uses host-derived growth factors to drive ERK phosphorylation and MCL1 expression to survive in the metastatic environment
Conclusion: Niche-derived growth fac tors drive MAPK activity and MCL1 expression in osteosarcoma, promoting metastatic colonization. Although later metastases produce less MCL1, they remain dependent on it. MCL1 is a promising target for clinical trials in both human and canine patients. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - May 3, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Source Type: research
Bent ab interno needle goniotomy versus gonioscopy-assisted transluminal trabeculotomy in primary open-angle glaucoma: study protocol of a randomized clinical trial
Minimally invasive glaucoma surgery (MIGS) is a new class of surgeries, which combines moderate to high success rates and a high safety profile. Bent Ab interno Needle Goniotomy (BANG) and Gonioscopy-Assisted ... (Source: Trials)
Source: Trials - May 3, 2024 Category: General Medicine Authors: Gabriel Ayub, Ticiana De Francesco and Vital Paulino Costa Tags: Study protocol Source Type: research
Efficacy of a mouthwash containing ε-poly-L-lysine, funme peptides and domiphen in reducing halitosis and supragingival plaque: a randomized clinical trial
To evaluate the antibacterial effectiveness of a combination of ε-poly-L-lysine (ε-PL), funme peptide (FP) as well as domiphen against oral pathogens, and assess the efficacy of a BOP® mouthwash supplemented w... (Source: BMC Oral Health)
Source: BMC Oral Health - May 3, 2024 Category: Dentistry Authors: Song Shen, Xu Liu, Jun Huang, Yi Sun, Bin Liu, Wenzhu Song, Lei Meng, Mi Du and Qiang Feng Tags: Research Source Type: research
Patient perspectives in adverse event reporting after vaginal apical prolapse surgery
Many clinical trials use systematic methodology to monitor adverse events (AE) and determine grade (severity), expectedness, and relatedness to treatments as determined by clinicians. However, patient perspective in the process remains lacking. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - May 3, 2024 Category: OBGYN Authors: Vivian W. SUNG, Shawn MENEFEE, Holly E. RICHTER, Pamela A. MOALLI, Uduak ANDY, Alison WEIDNER, David D. RAHN, Marie F. PARAISO, Sarah E. JENEY, Donna MAZLOOMDOOST, Jace GILBERT, Ryan WHITWORTH, Sonia THOMAS, NICHD Pelvic Floor Disorders Network Tags: Meeting Papers: Society of Gynecologic Surgeons Source Type: research
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians
T-cell redirecting therapies such as chimeric antigen receptor T-cells and bispecific antibodies, are emerging as a novel class of immunotherapeutic agents for treatment of relapsed refractory multiple myeloma (MM). Their use is associated with an increased risk of infectious adverse events, fostered by cytopenias, hypogammaglobulinemia and T-cell exhaustion. Multiple ongoing clinical trials and real-world studies are investigating safety of T-cell therapy, highlighting the need for strategies to prevent and monitor the risk of infection. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2024 Category: Hematology Authors: Tommaso Lupia, Lorenzo Cani, Sara Bringhen, Francesco Giuseppe De Rosa, Benedetto Bruno, Malgorzata Mikulska, Silvia Corcione, Roberto Mina Tags: Review Article Source Type: research
Heartfelt Advances: ACC 2024 Clinical Trials Spotlight-New Horizons in Heart Failure Management
The American College of Cardiology, 2024, (ACC.24) Annual Scientific Session offered a plethora of new clinical science within which were heart failure – centric data qualifying as transformative research and advances in clinical practice. Among the highlights were reaffirming trials, groundbreaking data, unanticipated results, and innovative therapeutic strategies with both null but informative data, and definitive outcomes. Regardless of the fi ndings, all of these data will lead to future work, either validating positive findings or further exploring null results. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 3, 2024 Category: Cardiology Authors: Jennifer Maning, Jonathan Hourmozdi, Sonu Abraham, Quentin Youmans, Jane Wilcox, Sanjiv Shah, Clyde Yancy Tags: Perspectives Source Type: research
Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial
This study has been registered with Chinese Clinical Trial Registry (ChiCTR2300070674). (Source: PLoS One)
Source: PLoS One - May 3, 2024 Category: Biomedical Science Authors: Yu-Hao Lin Source Type: research
